Some new aspects of the effect of (-)deprenyl in Parkinson's disease-a retrospective study

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

50 de novo patients with Parkinson's disease were investigated in a retrospective study after selegiline (-)deprenyl monotherapy and a combination of (-)deprenyl and levodopa. The study involved subjects with different Hoehn-Yahr stages (I, II, III, IV). During the treatment period the distribution of age (below 60 yr or above 60 yr) among the Hoehn-Yahr stages was similar to that of the baseline period, while the clinical disability for the patients starting with hypokinesis meant a more severe state compared to the cases with tremor. The sex ratio was similar during the baseline period but later, during the administration of deprenyl, the progression of males was slower than that of females. (-)Deprenyl was effective in decreasing the hypokinesis, while the rigidity was improved less by this drug. The reduction of parkinsonian symptoms developed slowly and was independent of the severity of Parkinson's disease. The maintenance of deprenyl monotherapy showed a high individual variation but the average period was about one year. The termination fo the effect of deprenyl was rapid, however, not progressive. The time of the appearance of the side effects of additional levodopa was not delayed by deprenyl treatment. After five years the severity of disease was similar to the baseline disability scores in spite of the combined therapy with levopoda and deprenyl.

Original languageEnglish
Pages (from-to)155-164
Number of pages10
JournalJournal of Neural Transmission - Parkinson's Disease and Dementia Section
Volume4
Issue number2
DOIs
Publication statusPublished - Jun 1992

Fingerprint

Selegiline
Parkinson Disease
Retrospective Studies
Levodopa
Age Distribution
Sex Ratio
Tremor
Therapeutics
Maintenance

Keywords

  • deprenyl
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

@article{8d5b67be5a9b43c68098ac99b5666a85,
title = "Some new aspects of the effect of (-)deprenyl in Parkinson's disease-a retrospective study",
abstract = "50 de novo patients with Parkinson's disease were investigated in a retrospective study after selegiline (-)deprenyl monotherapy and a combination of (-)deprenyl and levodopa. The study involved subjects with different Hoehn-Yahr stages (I, II, III, IV). During the treatment period the distribution of age (below 60 yr or above 60 yr) among the Hoehn-Yahr stages was similar to that of the baseline period, while the clinical disability for the patients starting with hypokinesis meant a more severe state compared to the cases with tremor. The sex ratio was similar during the baseline period but later, during the administration of deprenyl, the progression of males was slower than that of females. (-)Deprenyl was effective in decreasing the hypokinesis, while the rigidity was improved less by this drug. The reduction of parkinsonian symptoms developed slowly and was independent of the severity of Parkinson's disease. The maintenance of deprenyl monotherapy showed a high individual variation but the average period was about one year. The termination fo the effect of deprenyl was rapid, however, not progressive. The time of the appearance of the side effects of additional levodopa was not delayed by deprenyl treatment. After five years the severity of disease was similar to the baseline disability scores in spite of the combined therapy with levopoda and deprenyl.",
keywords = "deprenyl, Parkinson's disease",
author = "J. M{\'a}lly",
year = "1992",
month = "6",
doi = "10.1007/BF02251478",
language = "English",
volume = "4",
pages = "155--164",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Some new aspects of the effect of (-)deprenyl in Parkinson's disease-a retrospective study

AU - Málly, J.

PY - 1992/6

Y1 - 1992/6

N2 - 50 de novo patients with Parkinson's disease were investigated in a retrospective study after selegiline (-)deprenyl monotherapy and a combination of (-)deprenyl and levodopa. The study involved subjects with different Hoehn-Yahr stages (I, II, III, IV). During the treatment period the distribution of age (below 60 yr or above 60 yr) among the Hoehn-Yahr stages was similar to that of the baseline period, while the clinical disability for the patients starting with hypokinesis meant a more severe state compared to the cases with tremor. The sex ratio was similar during the baseline period but later, during the administration of deprenyl, the progression of males was slower than that of females. (-)Deprenyl was effective in decreasing the hypokinesis, while the rigidity was improved less by this drug. The reduction of parkinsonian symptoms developed slowly and was independent of the severity of Parkinson's disease. The maintenance of deprenyl monotherapy showed a high individual variation but the average period was about one year. The termination fo the effect of deprenyl was rapid, however, not progressive. The time of the appearance of the side effects of additional levodopa was not delayed by deprenyl treatment. After five years the severity of disease was similar to the baseline disability scores in spite of the combined therapy with levopoda and deprenyl.

AB - 50 de novo patients with Parkinson's disease were investigated in a retrospective study after selegiline (-)deprenyl monotherapy and a combination of (-)deprenyl and levodopa. The study involved subjects with different Hoehn-Yahr stages (I, II, III, IV). During the treatment period the distribution of age (below 60 yr or above 60 yr) among the Hoehn-Yahr stages was similar to that of the baseline period, while the clinical disability for the patients starting with hypokinesis meant a more severe state compared to the cases with tremor. The sex ratio was similar during the baseline period but later, during the administration of deprenyl, the progression of males was slower than that of females. (-)Deprenyl was effective in decreasing the hypokinesis, while the rigidity was improved less by this drug. The reduction of parkinsonian symptoms developed slowly and was independent of the severity of Parkinson's disease. The maintenance of deprenyl monotherapy showed a high individual variation but the average period was about one year. The termination fo the effect of deprenyl was rapid, however, not progressive. The time of the appearance of the side effects of additional levodopa was not delayed by deprenyl treatment. After five years the severity of disease was similar to the baseline disability scores in spite of the combined therapy with levopoda and deprenyl.

KW - deprenyl

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0026587899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026587899&partnerID=8YFLogxK

U2 - 10.1007/BF02251478

DO - 10.1007/BF02251478

M3 - Article

C2 - 1571079

AN - SCOPUS:0026587899

VL - 4

SP - 155

EP - 164

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 2

ER -